Physician profile
Richard Hall
NPI 1649474040
$29,270.15
in general payments reported to CMS, 2019-2025
16 companies · $4,897 in 2025
The $4,897 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,788 · 2021: $1,500 · 2022: $1,630 · 2024: $15K · 2025: $4,897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Travel and Lodging: $2,035 · Food and Beverage: $1,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,130.50 |
| Travel and Lodging | $2,034.76 |
| Food and Beverage | $1,187.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $8,558.11 | 2024 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $7,498.36 | 2019-2025 | |
| Abbvie INC. | $3,000.11 | 2025 | |
| Emd Serono, INC. | $2,850.00 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,295.00 | 2024 | Alunbrig |
| Jazz Pharmaceuticals INC. | $1,630.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,606.50 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $1,500.00 | 2021 | |
| Pfizer INC. | $186.26 | 2019 | |
| Tempus Ai, INC | $145.74 | 2024 | Xt Cdx |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.